Evidence map›Paper›PMID 31001563›Full record

ArticleJournal of immunology research2019

Immunobiotics Beneficially Modulate TLR4 Signaling Triggered by Lipopolysaccharide and Reduce Hepatic Steatosis In Vitro.

Paulraj Kanmani, AbuZar Ansari, Julio Villena, Hojun Kim

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Frontiers in pharmacology · 2021
    Article
  6. The Panda-DerivedFrontiers in immunology · 2021
    Article
  7. Article
  8. Frontiers in microbiology · 2020
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Paulraj KanmaniDepartment of Rehabilitation Medicine of Korean Medicine, Dongguk University, Goyang, Republic of Korea.ORCID 0000-0002-3924-8279
AbuZar AnsariDepartment of Rehabilitation Medicine of Korean Medicine, Dongguk University, Goyang, Republic of Korea.
Julio VillenaLaboratory of Immunobiotechnology, Reference Centre for Lactobacilli (CERELA-CONICET), Tucuman, Argentina.
Hojun KimDepartment of Rehabilitation Medicine of Korean Medicine, Dongguk University, Goyang, Republic of Korea.ORCID 0000-0003-1038-0142
Dongguk University · KRConsejo Nacional de Investigaciones Científicas y Técnicas · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic inflammation and injury may result from the translocation of pathological bacteria and their proinflammatory mediators. Probiotics attenuate hepatic diseases related to inflammation by exhibiting immunoregulatory effects. Therefore, this study was conducted to evaluate lipid reduction and immunoregulatory potentials of probiotic bacteria in vitro. HepG2 cells treated with total cellular fluid (TCF) of LABs reduced lipid accumulation. Moreover, cells responded to lipopolysaccharide (LPS) by producing higher levels of IL-6, IL-8, MCP-1, and TNF-

Indexed as

LactobacillalesSignal TransductionCytokinesFatty LiverFermented FoodsHep G2 CellsHumansInflammationLipopolysaccharidesProbioticsTHP-1 CellsToll-Like Receptor 4CytokinesLipopolysaccharidesTLR4 protein, humanToll-Like Receptor 4

Identifiers

PMID31001563
PMCPMC6437725
OpenAlexW2922127886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.